Dr. Helga Grupe appointed Chief Business Officer and Managing Director of Avontec GmbH
Changes in the Management of Avontec GmbH
Dr. Grupe has 16 years of experience in leadership roles in marketing and business development. She joined Avontec from Wilex AG, a publically traded German biopharmaceutical company where she served as Vice President of Business Development from 2000 to 2007. From 1996 to 2000, she held various positions with increasing responsibility in marketing and business development at Monsanto Deutschland GmbH, including Business Development Director of Europe. Prior to that, from 1995 to 1996, Dr. Grupe was Market Development Manager at Zeneca GmbH. From 1991 to 1994, she started and led the Biotechnology Co-ordination Center of the Federal State of Lower Saxony, Germany. Dr. Grupe received her PhD in biology at the University of Göttingen, Germany.
Dr. Thomas Schulze, Chief Executive Officer of Avontec said: “We are very pleased to have won a highly competent expert with Dr. Grupe, who is perfectly qualified to achieve Avontec's objectives in the field of business development, especially the conclusion of new partnerships for our clinical development programs.”
Dr. Grupe commented: “Avontec has established a powerful product base for multiple inflammatory diseases with the most advanced programs already in Phase 2. I am pleased to be joining their impressive team and look forward to contributing to the further growth of this dynamic company.”
AVONTEC is a biopharmaceutical company specialized in the development of novel nucleic acid based therapeutic treatments targeting transcription factors. Transcription factors are the master switches of gene regulation, able to turn genes on and off with exquisite sensitivity. The molecules developed at AVONTEC are designed to specifically attenuate abnormal transcription factor signaling, thereby normalizing the underlying cause of the disease. AVONTEC develops these decoy ODNs as therapeutic agents to treat chronic inflammation. AVONTEC's lead programs, AVT 01 in asthma and AVT 02 in inflammatory skin diseases, have been successfully advanced into Phase IIa clinical trials that are expected to be completed within 2008. In addition, there are several candidates in the pipeline based on AVONTEC's core decoy technology. AVONTEC operates based on a lean business model with a seasoned management team experienced in clinical development.